Rate Video

ESH AL 2018 | FLT3 inhibitors in the treatment of AML

Farhad Ravandi • 4 May 2018

Acute Myeloid Leukemia Leukemia Azacitidine Crenolanib Gilteritinib Midostaurin Quizartinib Sorafenib

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

NGS vs flow cytometry for MRD assessment in NPM1-mutated AML

Farhad Ravandi • 13 Dec 2021

MRD studies in ALL and AML

Farhad Ravandi • 9 Dec 2017

Ponatinib + venetoclax for the treatment of R/R Ph+ALL

Farhad Ravandi • 11 Jun 2022

Value of MRD in patients with NPM1-mutated AML

Farhad Ravandi • 11 Mar 2021

Related Videos

Outcomes of CLL patients following treatment with a covalent BTK and BCL2 inhibitor

Toby Eyre • 15 Jun 2022

Results of QuANTUM-First: quizartinib vs placebo plus intensive chemotherapy in FLT3-ITD+ AML

Harry Erba • 12 Jun 2022

Clinical trial updates in CML

Timothy Hughes • 12 Jun 2022

The management of high-risk ALL

Arnon Nagler • 12 Jun 2022